<DOC>
	<DOCNO>NCT03051685</DOCNO>
	<brief_summary>Crossover study compare BA DFN-15 3 different dos versus comparator determine dose-proportionality DFN-15 healthy volunteer fast condition</brief_summary>
	<brief_title>Bioavailabilityof DFN-15 3 Different Doses Versus Comparator Determine Dose-proportionality DFN-15 Healthy Volunteers Under Fasting Conditions</brief_title>
	<detailed_description />
	<criteria>Subjects male female , least 18 year age old 45 year age . The main inclusion criterion : 1. non exsmokers 2. body mass index ( BMI ) â‰¥18.50 kg/m2 &lt; 30.00 kg/m2 3. clinically significant abnormality find 12lead ECG perform study entry 4. negative pregnancy test female subject 5. healthy accord medical history , complete physical examination ( include vital sign ) laboratory test ( general biochemistry , hematology , urinalysis , coagulation ) 6 . Fecal occult blood determination negative screen 1 . Females pregnant lactate 2 . Patients history allergic reaction nonsteroidal antiinflammatory drug ( NSAIDs ) , include patient aspirin NSAIDs induce syndrome asthma , rhinitis , nasal polyps Samter 's triad 3 . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect 4 . History significant gastrointestinal , liver kidney disease may affect drug bioavailability 5 . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 6 . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease , neurological impairment cognitive dysfunction , opinion investigator , would compromise validity inform consent , study participation compliance data collection 7 . Presence outofrange cardiac interval and/ morphological change suggestive arrhythmias ischaemic heart disease screen electrocardiogram ( ECG ) clinically significant ECG abnormalities 8 . History current hypertension , bleed disorder , ischaemic heart disease , stroke and/or cerebrovascular disease renal disease 9 . History asthma , urticaria , allergictype reaction take acetylsalicylic acid ( ASA ) NSAIDs 10 . Presence history gastric , duodenal peptic ulcer gastrointestinal bleeding 11 . Use ASA NSAIDs , product contain ASA NSAIDs , previous 7 day day 1 study 12 . Known presence rare hereditary problem galactose /or lactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 13 . Maintenance therapy drug significant history drug dependency ( include marijuana medical marijuana ) alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) within 1 year 14 . Any clinically significant illness previous 28 day day 1 study 15 . Any history tuberculosis and/or prophylaxis tuberculosis 16 . Positive urine screen alcohol and/or drug abuse 17 . Positive result HIV Ag/Ab Combo , Hepatitis B surface Antigen ( HBsAG ( B ) ) anti Hepatitis C Virus ( HCV ( C ) ) test 18 . Females pregnant accord positive pregnancy test 19 . Volunteers take investigational product ( another clinical trial ) previous 28 day day 1 study already participate clinical study 20 . Volunteers donate plasma previous 14 day day 1 study 21 . Donation 500 mL blood ( American Red Cross , clinical study , etc . ) previous 56 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>